Fig. 5. Changes in metabolic and inflammatory parameters in humans with multiple ascending doses of AMG 133.
a–f, Mean (s.e.m.) change from baseline in fasting glucose, n = 5–8 for AMG 133 and n = 6 for placebo at day 1 (a), fasting insulin, n = 4–8 for AMG 133 and n = 5 for placebo at day 1 (b), fasting C-peptide n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (c), fasting glucagon, n = 3–8 for AMG 133 and n = 5 for placebo at day 1 (d), HbA1c, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (e) and hs-CRP, n = 6–8 for AMG 133 and n = 6 for placebo at day 1 (f) after MADs of AMG 133. Arrows indicate when the investigational product was administered at day 1, 29 and 57.